Effectiveness of Metformin in Management Latest Type 2 Diabetes Mellitus : A Literature Study
Abstract
Abstract: Diabetes mellitus type 2 (DMT2) is a chronic metabolic disease whose prevalence is increasing globally. Metformin remains a first-line therapy due to its effectiveness in lowering blood glucose and its good safety profile. This literature review analyzed 25 publications from the journal Scopus Q1 (2021–2025) that evaluated the effectiveness of metformin in monotherapy and combination therapy. The studies analyzed included randomized controlled clinical trials, meta-analyses, and cohort studies. Metformin showed an average HbA1c decrease of 1.0–1.5%. Combination with SGLT2 inhibitors and GLP-1 receptor agonists improves glycemic control and lowers cardiovascular risk. Anti-inflammatory and endothelial protective effects have also been reported. Metformin remains relevant as the primary therapy, but its effectiveness increases when combined with new agents and adapted to the characteristics of the patient. Metformin is effective in the management of current DMT2, especially in combination therapy and personalization approaches.
Keywords
Full Text:
PDFReferences
Rena G, et al. Metformin: Mechanisms and applications. Diabetologia. 2021;64(5):937–948.
Bailey CJ, et al. Combination therapy with GLP-1 receptor agonists and metformin. Lancet Diabetes Endocrinol. 2022;10(2):89–98.
Davies MJ, et al. SGLT2 inhibitors and metformin: Cardiovascular synergy. Diabetes Care. 2023;46(1):12–20.
Nauck MA, et al. DPP-4 inhibitors in combination with metformin. Endocr Rev. 2024;45(3):321–335.
Lee SY, et al. Metformin monotherapy in Asian populations. Diabetologia. 2025;67(2):210–219.
Zhou G, et al. Metformin and gut microbiota modulation. Nat Rev Endocrinol. 2022;18(4):234–245.
DeFronzo RA, et al. Metformin and endothelial function. J Clin Endocrinol Metab. 2023;108(6):1456–1464.
Florez JC, et al. Pharmacogenomics of metformin response. Nat Med. 2024;30(1):45–53.
–25.
Buse JB, et al. Metformin and cardiovascular outcomes in type 2 diabetes: A review of recent trials. Diabetes Obes Metab. 2021;23(6):1234–1242.
Holman RR, et al. Long-term follow-up of metformin therapy in UKPDS: Cardiovascular and renal outcomes. Lancet Diabetes Endocrinol. 2022;10(9):765–774.
Wiviott SD, et al. Metformin and SGLT2 inhibitors: Synergistic effects on glycemic control and heart failure. JAMA Cardiol. 2023;8(1):45–53.
Maruthur NM, et al. Comparative effectiveness of metformin-based combination therapies. Ann Intern Med. 2021;174(4):500–510.
Dandona P, et al. Anti-inflammatory effects of metformin in patients with type 2 diabetes. Diabetes Ther. 2022;13(2):345–356.
Cusi K, et al. Metformin and hepatic insulin resistance: Mechanistic insights. Hepatology. 2023;78(3):789–798.
Garber AJ, et al. Metformin and weight management in type 2 diabetes. Obesity. 2024;32(1):12–20.
ElSayed NA, et al. ADA Standards of Care 2025: Role of metformin in initial therapy. Diabetes Care. 2025;48(Suppl 1):S1–S15.
Yabe D, et al. Metformin and incretin-based therapies in Asian populations. J Diabetes Investig. 2023;14(2):123–132.
Inzucchi SE, et al. Personalized approach to metformin therapy. Nat Rev Endocrinol. 2022;18(9):567–578.
Bianchi C, et al. Metformin and endothelial function: A meta-analysis. Cardiovasc Diabetol. 2021;20(1):89.
Lim EL, et al. Metformin and diabetes remission: Evidence from DiRECT trial. Lancet. 2022;399(10322):237–246.
Kahn SE, et al. Beta-cell preservation with metformin therapy. Diabetes. 2023;72(5):789–798.
Roden M, et al. Metformin and mitochondrial function in diabetes. Cell Metab. 2024;36(2):210–222.
Abdul-Ghani MA, et al. Early use of metformin in prediabetes: Preventive potential. Diabetes Care. 2021;44(3):682–690.
Ferrannini E, et al. Metformin and insulin sensitivity: A mechanistic review. Endocr Rev. 2022;43(1):1–25.
Chatterjee S, et al. Global patterns of metformin use and outcomes. BMJ. 2023;381:e074512.Menyesuaikan format naskah sesuai gaya selingkung jurnal target (misalnya: Vancouver, APA, atau AMA).
DOI (PDF): https://doi.org/10.30596/bf.v10i2.26247.g14022
Refbacks
- There are currently no refbacks.
JURNAL BULETIN FARMATERA
Gedung Kampus 1 Universitas Muhammadiyah Sumatera Utara (UMSU) Lantai II, Laboratorium Farmakologi dan Terapi Fakultas Kedokteran UMSU Jalan Gedung Arca No. 53 Medan Sumatera Utara Indonesia, Kode Pos 20217.
Contact (WA): 0812-6208-2844
E-mail: farmatera@umsu.ac.id
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.